A study of multimodal treatment strategy for malignant hepatic tumors using high-dose intrarterial chemotherapy combined with direct hemoperfusion under hepatic venous isolation.

本研究已被用于建立一个多模态治疗策略，用于使用高剂量内化学疗法组合在Hepatic venous Isolation（HVI·DHP）下的恶性肿瘤的多模态治疗策略。在这个项目的第一年，我们演示了将血管紧张素II与HVI下的抗癌药物结合起来的用途--DHP进一步增加了药物输送到肝炎肿瘤。在补充中，主要抗逆转录药物的肝炎提取率包括肾上腺素，在先前的研究中没有完全被采纳，用HVI·DHP的援助进行了重新评价，并且在调查期间也是明确的。准确地说，在第二年，我们调查了HVI和DHP在Hepphic肿瘤的多模态治疗中的作用。这个临床研究清楚地演示了，因为高剂量化学疗法获得了对反应和生存都有好处，并且使用一个可植入的导管系统附加的低剂量内部化学疗法得到了进一步的延长。这些结果是一个强有力的指标，即将高剂量诱导治疗与低剂量维持治疗结合在一起，将为患者提供显著的治疗益处，以在当前的无望情况下使用先进的肝炎肿瘤。作为一个未来的方向，我们认为HVI·DHP的进一步技术简化是需要执行重复的高剂量治疗的。在这方面，我们目前已经设计了一个4-发光的或2-气球的天主教，谁可以承诺接受这种治疗？

This study was undetaken to establish a multimodal treatment strategy for malignat hepatic tumors using high-dose intraarterial chemotherapy combined direct hemoperfusion under hepatic venous isolation(HVI・DHP). In the first year of the term of this project, we demonstrated experimentally that a combined use of angiotensin II with anticancer drugs under HVI・DHP further increased drug delivery to hepatic tumors. In addition, the hepatic extraction rates of major anticacer drugs including adriamycin, which had not been fully elucidated in the previous studies, were reevaluated with the aid of HVI・DHP, and were clarified during this investigation. Accordingly in the second year, we investigated the role of high-dose chemotherapy under HVI・DHP in the multimodal treatment for hepatic tumors. This clinical study clearly demonstrated that both response and survival benefit obtained by high-dose chemothrapy was further prolonged with additional low-dose intraarterial chemotherapy using an implantable catheter system. These results strongly indicate that high-dose induction teratment combined with low-dose maintenance treatment would provide significant therapeutic benefits for patients with advanced hepatic tumors in currently hopeless situations. As a future direction, we consider that further technical simplification of HVI・DHP is required to perform repeated high-dose treatment. In this regard, we have currently designed a 4-lumen・2-balloen catheter, which may promote the world-wide acceptance of this treatment.